Skip to main content

Table 3 Prognostic significance of clinicopatholgic variables based on univariate analysis

From: Clinical significance of serum CA125 in diffuse malignant mesothelioma

 

No.

Median OS (months)

Survival at months (%)

Hazard ratio

P value

6

12

18

24

Age

1.881

0.147

 ≤60 years

28

13 ± 10.2

74.6

52.4

47.6

47.6

  

 >60 years

13

5 ± 2.2

34.6

26.0

26.0

26.0

  

Gender

1.850

0.157

 Male

28

43 ± 25.1

67.9

52.4

52.4

52.4

  

 Female

13

6 ± 2.8

45.1

22.6

11.3

11.3

  

Performance status (ECOG)

3.013

0.018

 0–1

33

13 ± 15.4

68.3

53.0

48.9

48.9

  

 2

8

2 ± 1.4

37.5

12.5

12.5

12.5

  

Primary tumor location

0.236

0.003

 Pleura

23

6 ± 2.1

51.5

22.9

22.9

22.9

  

 Pritoneum

18

88.9

68.8

61.9

61.9

  

Histological subtype

2.281

0.006

 Epithelial

14

43 ± 27.9

85.7

85.7

85.7

85.7

  

 Sarcomatoid

1

13

1

1

0

0

  

 Unspecified

26

6 ± 1.5

56.7

20.4

20.4

20.4

  

Surgery

0.363

0.069

 CRS

11

90.0

70.0

60.0

60.0

  

 nCRS

30

7 ± 2.0

52.1

35.8

35.8

35.8

  

Systemic chemotherapy

0.340

0.015

 Yes

23

43 ± 31.8

77.1

60.9

55.4

55.4

  

 No

18

4 ± 3.0

43.8

25.0

25.0

25.0

  

Local chemotherapy

0.486

0.156

 Yes

13

61.5

61.5

61.5

61.5

  

 No

28

9 ± 2.1

61.6

37.3

32.0

32.0

  

Stage of disease

11.495

0.017

 III

10

88.9

88.9

88.9

88.9

  

 IV

31

7 ± 2.5

52.1

31.0

26.6

26.6

  

Baseline of CA125

2.214

0.045

 ≤280 U/ml

28

43 ± 23.4

70.6

57.7

52.9

52.9

  

 >280 U/ml

13

5 ± 1.7

44.9

17.9

17.9

17.9

  
  1. –, did not reach the median OS